세계의 분열정동장애 시장 보고서(2025년)

Schizoaffective Disorder Global Market Report 2025

US $ 4,490 ￦ 6,344,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,170,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,996,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

분열정동장애 시장 규모는 향후 수년간 강력한 성장이 전망될 예정입니다. 시장의 헬스케어 인프라 확대, 맞춤형 의료 어프로치의 대두 등이 있습니다.

신경 질환의 유병률 증가는 분열정동장애 시장의 확대를 촉진할 것으로 예측됩니다. 신경 질환은 뇌, 척수, 신경을 포함한 신경계에 영향을 미쳐 다양한 인지, 운동 및 감각 기능 장애를 유발합니다. 신경 병증 증가 요인으로는 유전자 변이, 감염, 외상, 환경 독소,자가 면역 반응, 변성 과정 등이 있습니다. 이러한 질환의 유병률이 증가함에 따라 공통된 생물학적 메커니즘, 진단 능력의 발전, 의식의 높아짐에 따라 분열정동장애 진단 증가를 가져오고 있습니다. 2023년 4월, 미국에 본사를 둔 의학 연구 기관인 국립 의학 도서관은 약 670만 명의 미국인이 알츠하이머병을 앓고 있다고 보고해 2060년까지 1,380만명으로 증가할 것으로 예측했습니다.

분열정동장애 시장의 주요 기업은 치료효과를 높이고 환자의 순응도를 개선하고 투여횟수를 줄이기 위해 서방형 주사현탁제제 등 혁신적인 제제의 개발에 주력하고 있습니다. 서방형 주사제 현탁액(Extended-release injectable suspension drugs)은 유효성분을 장기간에 걸쳐 서서히 방출하는 제제로 기존의 즉시방출형 약제에 비해 투여횟수를 줄일 수 있습니다. Luye Pharma Group Ltd.는 미국 식품의약국(FDA)으로부터 정신분열증 및 분열정동장애의 치료제로서 ERZOFRI(팔미트산팔리페리돈) 서방형 주사용 현탁액의 승인을 취득했습니다. 물체 수준을 일정하게 유지하기 위해 투여 횟수를 줄이고, 환자의 복약 준수를 향상시키고, 재발의 위험을 저하시킵니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계 분열정동장애 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업의 분석
• 세계 분열정동장애 시장 : 성장률 분석
• 세계 분열정동장애 시장 실적 : 규모와 성장, 2019-2024
• 세계 분열정동장애 시장 예측 : 규모와 성장, 2024-2029, 2034F
• 세계 분열정동장애 전체 시장 규모(TAM)

제6장 시장 세분화

• 세계의 분열정동장애 시장 : 약물에 의한 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 항정신병약
• 기분 안정제
• 항우울제
• 항경련제
• 세계의 분열정동장애 시장 : 원인별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 유전적 요인
• 환경 요인
• 화학적 요인
• 세계의 분열정동장애 시장 : 최종 사용자별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 병원
• 클리닉
• 기타 최종 사용자
• 세계의 분열정동장애시장 : 항정신병약유형별 하위세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 비정형 항정신병약
• 정형항정신병약
• 세계의 분열정동장애 시장 : 기분 안정제유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 리튬
• 발프로산
• 라모트리긴
• 카르바마제핀
• 세계의 분열정동장애 시장 : 항우울제유형별 하위세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 선택적 세로토닌 재 흡수 억제제(SSRI)
• 세로토닌 노르에피네프린 재흡수 억제제(SNRI)
• 삼환계 항우울제(TCA)
• 모노아민산화효소 억제제(MAOI)
• 세계의 분열정동장애시장 : 항간질약유형별 하위세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 라모트리긴
• 발프로산
• 토피라마트
• 레베티라세탐

제7장 지역별/국가별 분석

• 세계의 분열정동장애 시장 : 지역별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 세계의 분열정동장애 시장 : 국가별, 분석과 예측, 2019-2024, 2024-2029F, 2034F

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

• 분열정동장애시장 : 경쟁 구도
• 분열정동장애 시장 : 기업 프로파일
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis

제31장 기타 주요 기업 및 혁신 기업

• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Boehringer Ingelheim International GmbH
• Zydus Lifesciences Limited
• Neurocrine Biosciences Inc.
• Alkermes Inc.
• Luye Pharma Group Ltd.
• Merz Pharma GmbH & Co. KGaA
• Acadia Pharmaceuticals Inc.
• Intra-Cellular Therapies Inc.
• Cerevel Therapeutics Inc.
• Avanir Pharmaceuticals Inc.
• Otsuka Pharmaceutical Co. Ltd.
• Reviva Pharmaceuticals Inc.
• Zogenix Inc.

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

• 분열정동장애 시장 2029 : 새로운 기회를 제공하는 국가
• 분열정동장애 시장 2029 : 새로운 기회를 제공하는 부문
• 분열정동장애 시장 2029 : 성장 전략
  • 시장 동향에 기초한 전략
  • 경쟁 전략

제36장 부록

SHW

영문 목차

영문목차

Schizoaffective disorder is a chronic mental illness that combines symptoms of schizophrenia, such as delusions and hallucinations, with mood disorder symptoms, including depressive or manic episodes. Managing this condition requires a multidisciplinary approach that integrates both therapeutic and pharmaceutical interventions to address its complex nature.

The primary medications used to treat schizoaffective disorder include antipsychotic medications, mood stabilizers, antidepressants, and anticonvulsants. Antipsychotic medications help control psychotic symptoms such as hallucinations, delusions, and disorganized thinking. The disorder can be influenced by genetic, environmental, and chemical factors. Treatment is provided in various healthcare settings, including hospitals, clinics, and other medical facilities.

The schizoaffective disorder market research report is one of a series of new reports from The Business Research Company that provides schizoaffective disorder market statistics, including the schizoaffective disorder industry's global market size, regional shares, competitors with a schizoaffective disorder market share, detailed schizoaffective disorder market segments, market trends and opportunities, and any further data you may need to thrive in the schizoaffective disorder industry. This schizoaffective disorder market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The schizoaffective disorder market size has grown strongly in recent years. It will grow from $7.36 billion in 2024 to $7.77 billion in 2025 at a compound annual growth rate (CAGR) of 5.5%. The growth during the historic period can be attributed to increased awareness of mental health disorders, improved diagnostic criteria, higher healthcare funding, expanded access to mental health services, a rising prevalence of mental health conditions, and greater availability of treatments for psychiatric illnesses.

The schizoaffective disorder market size is expected to see strong growth in the next few years. It will grow to $9.47 billion in 2029 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to the rising prevalence of mental health conditions, increased investment in psychiatric drug development, growing public awareness of mental illnesses, expanding healthcare infrastructure in emerging markets, and the rise of personalized medicine approaches. Key trends include the development of atypical antipsychotics, advancements in digital health platforms, innovation in long-acting injectable medications, improved diagnostic tools, the integration of AI in therapy management, and enhancements in psychotherapeutic techniques.

The increasing prevalence of neurological disorders is expected to drive the expansion of the schizoaffective disorder market. Neurological disorders affect the nervous system, including the brain, spinal cord, and nerves, leading to various cognitive, motor, and sensory dysfunctions. Factors contributing to the rise in neurological disorders include genetic mutations, infections, traumatic injuries, environmental toxins, autoimmune responses, and degenerative processes. The growing prevalence of these conditions has led to an increase in schizoaffective disorder diagnoses due to shared biological mechanisms, advancements in diagnostic capabilities, and heightened awareness. For example, in April 2023, the National Library of Medicine, a US-based medical research institution, reported that approximately 6.7 million Americans were living with Alzheimer's disease, with projections indicating an increase to 13.8 million by 2060. As a result, the rising incidence of neurological disorders is fueling the growth of the schizoaffective disorder market.

Leading companies in the schizoaffective disorder market are focusing on the development of innovative drug formulations, such as extended-release injectable suspension drugs, to enhance treatment efficacy, improve patient adherence, and reduce dosing frequency. Extended-release injectable suspension drugs are formulated to release their active ingredients gradually over an extended period, allowing for less frequent dosing compared to traditional immediate-release medications. For instance, in July 2024, Luye Pharma Group Ltd., a China-based pharmaceutical company, received approval from the US Food and Drug Administration (FDA) for ERZOFRI (paliperidone palmitate) extended-release injectable suspension for the treatment of schizophrenia and schizoaffective disorder. This long-acting injectable formulation ensures a consistent medication level in the body, reducing the frequency of administration, improving patient adherence, and lowering the risk of relapse. The convenience of fewer injections compared to oral medications significantly enhances the quality of life for individuals with chronic mental health conditions.

In March 2024, Bristol Myers Squibb, a US-based biopharmaceutical company, acquired Karuna Therapeutics Inc. for an undisclosed amount. This acquisition aims to strengthen Bristol Myers Squibb's neuroscience portfolio by incorporating Karuna Therapeutics' innovative schizophrenia treatment, KarXT, along with its early-stage pipeline. Karuna Therapeutics Inc., a US-based biopharmaceutical company, specializes in developing treatments for psychiatric and neurological conditions, including schizophrenia.

Major players in the schizoaffective disorder market are Pfizer Inc., Johnson & Johnson, Bristol Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Zydus Lifesciences Limited, Neurocrine Biosciences Inc., Alkermes Inc., Luye Pharma Group Ltd., Merz Pharma GmbH & Co. KGaA, Acadia Pharmaceuticals Inc., Intra-Cellular Therapies Inc., Cerevel Therapeutics Inc., Avanir Pharmaceuticals Inc., Otsuka Pharmaceutical Co. Ltd., Reviva Pharmaceuticals Inc., Zogenix Inc., Sunovion Pharmaceuticals Inc., Newron Pharmaceuticals S.p.A., Sage Therapeutics Inc., Lyndra Therapeutics Inc., BioXcel Therapeutics Inc.

North America was the largest region in the schizoaffective disorder market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in schizoaffective disorder report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the schizoaffective disorder market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The schizoaffective disorder market consists of revenues earned by entities by providing services such as clinical interviews, psychological assessments, cognitive-behavioral therapy (CBT), interpersonal therapy, and vocational rehabilitation. The market value includes the value of related goods sold by the service provider or included within the service offering. The schizoaffective disorder market includes sales of drugs such as risperidone, olanzapine, lithium and valproate, and fluoxetine or sertraline. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Schizoaffective Disorder Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on schizoaffective disorder market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for schizoaffective disorder ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The schizoaffective disorder market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drugs: Antipsychotic Medication; Mood Stabilizers; Antidepressant Medication; Anticonvulsants
• 2) By Causes: Genetic Factors; Environmental Factors; Chemical Factors
• 3) By End User: Hospitals; Clinics; Other End User
• Subsegments:
• 1) By Antipsychotic Medication: Atypical Antipsychotics; Typical Antipsychotics
• 2) By Mood Stabilizers: Lithium; Valproate; Lamotrigine; Carbamazepine
• 3) By Antidepressant Medication: Selective Serotonin Reuptake Inhibitors (SSRIs); Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs); Tricyclic Antidepressants (TCAs); Monoamine Oxidase Inhibitors (MAOIs)
• 4) By Anticonvulsants: Lamotrigine; Valproate; Topiramate; Levetiracetam
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Bristol Myers Squibb Company; AstraZeneca PLC; Abbott Laboratories
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Schizoaffective Disorder Market Characteristics

3. Schizoaffective Disorder Market Trends And Strategies

4. Schizoaffective Disorder Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Schizoaffective Disorder Growth Analysis And Strategic Analysis Framework

• 5.1. Global Schizoaffective Disorder PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Schizoaffective Disorder Market Growth Rate Analysis
• 5.4. Global Schizoaffective Disorder Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Schizoaffective Disorder Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Schizoaffective Disorder Total Addressable Market (TAM)

6. Schizoaffective Disorder Market Segmentation

• 6.1. Global Schizoaffective Disorder Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antipsychotic Medication
• Mood Stabilizers
• Antidepressant Medication
• Anticonvulsants
• 6.2. Global Schizoaffective Disorder Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Genetic Factors
• Environmental Factors
• Chemical Factors
• 6.3. Global Schizoaffective Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Other End User
• 6.4. Global Schizoaffective Disorder Market, Sub-Segmentation Of Antipsychotic Medication, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Atypical Antipsychotics
• Typical Antipsychotics
• 6.5. Global Schizoaffective Disorder Market, Sub-Segmentation Of Mood Stabilizers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lithium
• Valproate
• Lamotrigine
• Carbamazepine
• 6.6. Global Schizoaffective Disorder Market, Sub-Segmentation Of Antidepressant Medication, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Selective Serotonin Reuptake Inhibitors (SSRIs)
• Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
• Tricyclic Antidepressants (TCAs)
• Monoamine Oxidase Inhibitors (MAOIs)
• 6.7. Global Schizoaffective Disorder Market, Sub-Segmentation Of Anticonvulsants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lamotrigine
• Valproate
• Topiramate
• Levetiracetam

7. Schizoaffective Disorder Market Regional And Country Analysis

• 7.1. Global Schizoaffective Disorder Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Schizoaffective Disorder Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Schizoaffective Disorder Market

• 8.1. Asia-Pacific Schizoaffective Disorder Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Schizoaffective Disorder Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Schizoaffective Disorder Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Schizoaffective Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Schizoaffective Disorder Market

• 9.1. China Schizoaffective Disorder Market Overview
• 9.2. China Schizoaffective Disorder Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Schizoaffective Disorder Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Schizoaffective Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Schizoaffective Disorder Market

• 10.1. India Schizoaffective Disorder Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Schizoaffective Disorder Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Schizoaffective Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Schizoaffective Disorder Market

• 11.1. Japan Schizoaffective Disorder Market Overview
• 11.2. Japan Schizoaffective Disorder Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Schizoaffective Disorder Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Schizoaffective Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Schizoaffective Disorder Market

• 12.1. Australia Schizoaffective Disorder Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Schizoaffective Disorder Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Schizoaffective Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Schizoaffective Disorder Market

• 13.1. Indonesia Schizoaffective Disorder Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Schizoaffective Disorder Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Schizoaffective Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Schizoaffective Disorder Market

• 14.1. South Korea Schizoaffective Disorder Market Overview
• 14.2. South Korea Schizoaffective Disorder Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Schizoaffective Disorder Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Schizoaffective Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Schizoaffective Disorder Market

• 15.1. Western Europe Schizoaffective Disorder Market Overview
• 15.2. Western Europe Schizoaffective Disorder Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Schizoaffective Disorder Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Schizoaffective Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Schizoaffective Disorder Market

• 16.1. UK Schizoaffective Disorder Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Schizoaffective Disorder Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Schizoaffective Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Schizoaffective Disorder Market

• 17.1. Germany Schizoaffective Disorder Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Schizoaffective Disorder Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Schizoaffective Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Schizoaffective Disorder Market

• 18.1. France Schizoaffective Disorder Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Schizoaffective Disorder Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Schizoaffective Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Schizoaffective Disorder Market

• 19.1. Italy Schizoaffective Disorder Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Schizoaffective Disorder Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Schizoaffective Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Schizoaffective Disorder Market

• 20.1. Spain Schizoaffective Disorder Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Schizoaffective Disorder Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Schizoaffective Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Schizoaffective Disorder Market

• 21.1. Eastern Europe Schizoaffective Disorder Market Overview
• 21.2. Eastern Europe Schizoaffective Disorder Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Schizoaffective Disorder Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Schizoaffective Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Schizoaffective Disorder Market

• 22.1. Russia Schizoaffective Disorder Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Schizoaffective Disorder Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Schizoaffective Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Schizoaffective Disorder Market

• 23.1. North America Schizoaffective Disorder Market Overview
• 23.2. North America Schizoaffective Disorder Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Schizoaffective Disorder Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Schizoaffective Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Schizoaffective Disorder Market

• 24.1. USA Schizoaffective Disorder Market Overview
• 24.2. USA Schizoaffective Disorder Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Schizoaffective Disorder Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Schizoaffective Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Schizoaffective Disorder Market

• 25.1. Canada Schizoaffective Disorder Market Overview
• 25.2. Canada Schizoaffective Disorder Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Schizoaffective Disorder Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Schizoaffective Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Schizoaffective Disorder Market

• 26.1. South America Schizoaffective Disorder Market Overview
• 26.2. South America Schizoaffective Disorder Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Schizoaffective Disorder Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Schizoaffective Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Schizoaffective Disorder Market

• 27.1. Brazil Schizoaffective Disorder Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Schizoaffective Disorder Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Schizoaffective Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Schizoaffective Disorder Market

• 28.1. Middle East Schizoaffective Disorder Market Overview
• 28.2. Middle East Schizoaffective Disorder Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Schizoaffective Disorder Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Schizoaffective Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Schizoaffective Disorder Market

• 29.1. Africa Schizoaffective Disorder Market Overview
• 29.2. Africa Schizoaffective Disorder Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Schizoaffective Disorder Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Schizoaffective Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Schizoaffective Disorder Market Competitive Landscape And Company Profiles

• 30.1. Schizoaffective Disorder Market Competitive Landscape
• 30.2. Schizoaffective Disorder Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis

31. Schizoaffective Disorder Market Other Major And Innovative Companies

• 31.1. Takeda Pharmaceutical Company Limited
• 31.2. Eli Lilly and Company
• 31.3. Boehringer Ingelheim International GmbH
• 31.4. Zydus Lifesciences Limited
• 31.5. Neurocrine Biosciences Inc.
• 31.6. Alkermes Inc.
• 31.7. Luye Pharma Group Ltd.
• 31.8. Merz Pharma GmbH & Co. KGaA
• 31.9. Acadia Pharmaceuticals Inc.
• 31.10. Intra-Cellular Therapies Inc.
• 31.11. Cerevel Therapeutics Inc.
• 31.12. Avanir Pharmaceuticals Inc.
• 31.13. Otsuka Pharmaceutical Co. Ltd.
• 31.14. Reviva Pharmaceuticals Inc.
• 31.15. Zogenix Inc.

32. Global Schizoaffective Disorder Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Schizoaffective Disorder Market

34. Recent Developments In The Schizoaffective Disorder Market

35. Schizoaffective Disorder Market High Potential Countries, Segments and Strategies

• 35.1 Schizoaffective Disorder Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Schizoaffective Disorder Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Schizoaffective Disorder Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료